Rheumatoid arthritis

News

MSD advances on a broad front with TL1A drug tulisokibart

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

X-ray of the hand in rheumatoid arthritis

Istesso backer sees silver lining in failed arthritis trial

Shares in the UK's IP Group slid today after it said that an arthritis drug in development at portfolio company Istesso had failed a phase 2b trial.

News

Apple devices enrich patent data in arthritis trial

It can be challenging to follow the course of rheumatoid arthritis accurately in clinical assessments and trials due to “subtle and unpredictable” changes in symptoms – bu

News

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Ita

News

Gilead adds lupus, arthritis therapies with EVOQ alliance

US biotech EVOQ Therapeutics has lined up another partner for its NanoDisc immunotherapy technology, with Gilead Sciences buying into the platform in a deal valued at up to $658.5 million.<

News

GSK shelves arthritis blockbuster hope otilimab after lacklu...

GSK has said it will not be able to move ahead with regulatory filings for otilimab as a treatment for rheumatoid arthritis (RA), after it failed to show the desired level of efficacy in tw

MSD advances on a broad front with TL1A drug tulisokibart

Istesso backer sees silver lining in failed arthritis trial

Apple devices enrich patent data in arthritis trial

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Gilead adds lupus, arthritis therapies with EVOQ alliance

GSK shelves arthritis blockbuster hope otilimab after lacklu...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Rheumatoid arthritis

Editor's Picks